Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Rhea-AI Summary

Nexalin (Nasdaq: NXL) highlighted a growing peer-reviewed neuroimaging literature supporting its Deep Intracranial Frequency Stimulation (DIFS™) as a non-invasive approach that modulates deep brain networks across mood, military, and memory indications.

Key studies include a randomized, double-blind, sham-controlled trial showing objective gamma‑frequency normalization via MEG/EEG and multiple fMRI/PET reports linking network changes to clinical improvement.

Positive

• Randomized double-blind sham-controlled trial showing objective gamma normalization
• Published imaging evidence across MRI, fMRI, MEG, EEG, and PET
• Peer-reviewed studies report network-level effects in Alzheimer’s, mood, PTSD/TBI, and ADHD

Negative

• Regulatory pathway with the FDA is described as ongoing, not completed
• No financial or commercialization milestones disclosed in the announcement

News Market Reaction

+0.58%

2 alerts

+0.58% News Effect

-9.5% Trough Tracked

+$62K Valuation Impact

$11M Market Cap

0.1x Rel. Volume

On the day this news was published, NXL gained 0.58%, reflecting a mild positive market reaction. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $62K to the company's valuation, bringing the market cap to $11M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.6200 Vol: Volume 38,970 is light at...

low vol

$0.6200 Last Close

Volume Volume 38,970 is light at 0.34x the 20-day average of 114,294 shares ahead of this research-focused release. low

Technical Shares trade below the 200-day MA, with price at $0.57 versus a 200-day MA of $1.07, and sit close to the 52-week low of $0.54 and well under the $3.87 52-week high.

Peers on Argus

Sector peers showed mixed moves, from -9.09% (AIMD) and -8.52% (CODX) to a stron...

Sector peers showed mixed moves, from -9.09% (AIMD) and -8.52% (CODX) to a strong gain of +26.65% (NVNO), while NXL was nearly flat at +0.02%, suggesting today’s article is more company-specific than part of a uniform sector rotation.

Historical Context

5 past events · Latest: Jan 23 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 23	Nasdaq compliance notice	Negative	-3.9%	Nasdaq notified NXL of non-compliance with the $1.00 minimum bid rule.
Jan 14	ADHD clinical data	Positive	+8.1%	Peer-reviewed ADHD trial showed improved attention and normalized brain activity with DIFS™.
Dec 03	FDA Q-Submission meeting	Positive	+1.6%	Completed FDA Q-Submission meeting for Gen-2 SYNC™ in Alzheimer’s with clear trial framework.
Dec 02	Investor webinar	Positive	+5.4%	Announced investor webinar highlighting DIFS™, AI monitoring, and global expansion plans.
Nov 18	Addiction case report	Positive	-1.9%	Case report on gambling disorder with alcohol use showed abstinence and no adverse effects.

Pattern Detected

Recent history shows NXL’s share price typically moves in the same direction as the perceived news tone, with only one divergence where positive clinical news coincided with a modest decline.

Recent Company History

Over the last few months, Nexalin has alternated between regulatory and clinical milestones and capital-markets updates. A Nasdaq minimum bid price notice on Jan 23, 2026 saw shares fall 3.9%, contrasting with an ADHD clinical trial update on Jan 14, 2026 that drove an 8.12% gain. Earlier, an FDA Q-Submission meeting for the Gen-2 SYNC™ console on Dec 3, 2025 and an investor webinar on Dec 2, 2025 produced modest positive reactions. A promising gambling-disorder case report on Nov 18, 2025 led to a 1.85% decline, showing not all positive clinical items lift the stock.

Market Pulse Summary

This announcement consolidates Nexalin’s peer-reviewed neuroimaging and clinical data across indicat...

Analysis

This announcement consolidates Nexalin’s peer-reviewed neuroimaging and clinical data across indications such as insomnia, depression, PTSD, Alzheimer’s disease, and ADHD, emphasizing objective modulation of deep brain networks. Historically, similar research and regulatory updates have sometimes led to meaningful moves, as seen with the ADHD study’s 8.12% gain, but other positive items had muted or negative follow-through. Investors may watch for future FDA interactions, larger controlled studies, and commercialization progress to gauge how this scientific foundation translates into business traction.

Key Terms

functional mri (fmri), magnetoencephalography (meg), electroencephalography (eeg), positron emission tomography (pet), +3 more

7 terms

functional mri (fmri) medical

"advanced modalities, including MRI, functional MRI (fMRI), magnetoencephalography"

Functional MRI (fMRI) is a non-invasive brain imaging technique that maps changes in blood flow to show which areas of the brain are active, like a live heat map of neural activity. For investors, fMRI matters because it is a tool used in drug development, medical-device testing and clinical studies to demonstrate how a treatment or technology affects the brain, which can influence regulatory approval, commercial value and market adoption.

magnetoencephalography (meg) medical

"including MRI, functional MRI (fMRI), magnetoencephalography (MEG), electroencephalography"

Magnetoencephalography (MEG) is a noninvasive brain-imaging technique that detects the tiny magnetic fields produced by nerve cell activity, like using an extremely sensitive microphone to ‘listen’ to the brain’s electrical conversations. For investors, MEG matters because it can become a tool for diagnosing neurological conditions, guiding treatments, validating drug or device effects, and creating commercial opportunities for companies developing medical imaging equipment, clinical services, or neurotechnology products.

electroencephalography (eeg) medical

"magnetoencephalography (MEG), electroencephalography (EEG), and positron emission"

Electroencephalography (EEG) records the brain’s electrical activity through sensors placed on the scalp, capturing patterns of brain waves much like a seismograph records tremors. Investors care because EEG data are used to show how neurological drugs, devices and diagnostic tools affect the brain, influencing clinical trial results, regulatory approvals and market adoption that drive a company’s revenue and development timeline.

positron emission tomography (pet) medical

"electroencephalography (EEG), and positron emission tomography (PET). These objective"

Positron emission tomography (PET) is a medical imaging method that uses tiny amounts of radioactive tracer to create detailed pictures of biological activity inside the body, like a camera that highlights where cells are most active. For investors, PET matters because it helps diagnose disease, track how well drugs or treatments are working, and drives demand for scanners, tracer production and clinical trial services—factors that can affect company revenues and regulatory outcomes.

randomized, double-blind, sham-controlled trial medical

"Most recently, a randomized, double-blind, sham-controlled trial published in Molecular"

A randomized, double-blind, sham-controlled trial is a study where participants are randomly assigned to receive either the real medical treatment or a convincing fake version (a 'sham'), and neither the participants nor the researchers know who got which. Like flipping a coin for assignment and keeping the result hidden, this design limits unintentional influence and placebo effects, so results give investors much stronger, clearer evidence about whether a treatment actually works and is safe—information that directly affects regulatory approval, market adoption, and company value.

neuroimaging medical

"advanced neuroimaging, and other bioelectrical biomarkers administered pre- and"

Neuroimaging is the set of medical techniques that create pictures or maps of the brain’s structure and activity, like using a camera or GPS to see what parts of the brain look like and how they behave. For investors, neuroimaging matters because it provides objective evidence used in clinical trials, product development and regulatory decisions, helping judge whether a therapy or device is likely to work, reduce risk, and reach the market.

non-invasive brain stimulation medical

"evidence-based non-invasive brain stimulation—positioning Nexalin’s DIFS™ technology"

Non-invasive brain stimulation is a set of medical techniques that use external devices—such as magnetic pulses or mild electrical fields—to gently modulate brain activity without surgery or implants. For investors, it signals a growing class of therapies and diagnostics that can expand treatment options for neurological and psychiatric conditions, influence regulatory and reimbursement decisions, and create new markets or competitive risks for companies developing devices or services, much like a remote control adjusting how a device behaves.

AI-generated analysis. Not financial advice.

Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its “mood-military-memory” clinical business plan with the FDA by publishing and submitting extensive clinical data.

Recent peer-reviewed and published data collectively span Insomnia and Depression (mood), traumatic brain injury and PTSD (military), Alzheimer’s disease (memory), and, most recently, attention deficit hyperactivity disorder (ADHD). Together, this body of clinical evidence continues to support Nexalin’s clinical business plan presented in recent pre-submission meetings with the FDA.

Nexalin’s growing body of published data consistently demonstrates objective normalization of abnormal brain activity and network function. This normalization of abnormal brain function is validated through traditional patient symptom surveys, advanced neuroimaging, and other bioelectrical biomarkers administered pre- and post-treatment.

Unlike inferior proposed neurostimulation devices that rely on minimal localized, surface-level stimulation, Nexalin’s clinical research has consistently incorporated objective bioelectrical brain imaging data using advanced modalities, including MRI, functional MRI (fMRI), magnetoencephalography (MEG), electroencephalography (EEG), and positron emission tomography (PET). These objective measures demonstrate engagement and regulation of deep disturbed brain networks associated with mental health disorders. The collective dataset also demonstrates Nexalin’s ability to penetrate and treat networks deep in the brain, rather than relying on superficial or localized effects offered by other stimulators.

“Across multiple independent studies, we are not just observing that patients feel better—we are seeing measurable changes in how the brain functions,” said Mark White, CEO of Nexalin Technology. “That distinction matters. Nexalin is a powerful whole-brain neurostimulation medical device that evidence indicates can penetrate deep in the brain to dramatically increase positive treatment response. Nexalin is not another battery-operated internet device sold to consumers. Our DIFS™ technology is designed to regulate abnormal neural signaling and normalize disrupted brain networks, and we have objective imaging data to support that mechanism.”

Most recently, a randomized, double-blind, sham-controlled trial published in Molecular Psychiatry demonstrated that Nexalin’s non-invasive DIFS™ neurostimulation produced objective normalization of abnormal gamma-frequency brain activity measured with MEG and EEG. The study showed improved communication across brain networks associated with attention, cognitive control, mood, sleep, and social functioning—directly linking clinical outcomes to measurable changes in brain activity.

Earlier peer-reviewed publications have demonstrated similar network-level effects in other indications:

• Alzheimer’s disease and dementia: Multiple studies published in Alzheimer’s Research & Therapy, Journal of Alzheimer’s Disease, and Radiology showed that DIFS™ stimulation improved cognition while enhancing hippocampal activation, restoring regional neuronal synchronization, and strengthening connectivity across memory and executive function networks measured by fMRI.
• Mood disorders: A randomized controlled trial published in Brain Stimulation demonstrated statistically significant separation between patients receiving Nexalin’s DIFS™ technology combined with standard antidepressant therapy versus medication alone, supported by objective changes in brain electrical activity.
• PTSD, TBI, and warfighter populations: Prior research has demonstrated Nexalin’s ability to regulate disrupted neural signaling associated with trauma-related conditions, supporting its potential role in restoring abnormal brain network function following injury and stress.
• Addiction and impulse control disorders: A peer-reviewed case report published in The American Journal on Addictions documented sustained abstinence and improved cognitive control following Nexalin treatment, suggesting durable neuroplastic effects beyond short-term behavioral change.

Across these studies, Nexalin’s DIFS™ technology has shown the ability to deliver frequency-specific stimulation that penetrates deep brain structures and influences large-scale neural networks—without invasive procedures or pharmaceuticals.

“Modern neuroscience increasingly recognizes mental health conditions as disorders of brain network regulation, not simply chemical imbalances,” said Dr. David Owens, Chief Medical Officer of Nexalin. “What makes Nexalin’s data compelling is the consistency. Across conditions, imaging modalities, and independent research groups, we see normalization of abnormal neural activity that aligns with clinical improvement. That level of objective validation is rare in non-invasive brain stimulation.”

Nexalin believes this expanding research foundation clearly differentiates its technology by demonstrating deep, whole-brain engagement supported by objective imaging—rather than surface-level stimulation or symptom-based claims.

As Nexalin continues to advance its next-generation neurostimulation platforms, the Company remains focused on building one of the most comprehensive, imaging-supported bodies of evidence in non-invasive brain stimulation—positioning Nexalin’s DIFS™ technology as a scientifically grounded approach to regulating dysfunctional brain activity underlying complex mental health and neurological disorders.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's medical devices are believed to be non-invasive and undetectable to the human body.  The Nexalin products are developed to provide relief to those afflicted with mental health issues using bioelectronic medical technology. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:

Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

FAQ

What did Nexalin (NXL) announce on February 2, 2026 about its DIFS™ research?

Nexalin announced a growing body of peer-reviewed neuroimaging studies validating DIFS™ across multiple conditions. According to the company, publications include a randomized, double-blind trial plus fMRI, MEG, EEG, and PET studies linking network changes to clinical improvement.

Does the February 2, 2026 Nexalin (NXL) release cite randomized controlled evidence for DIFS™?

Yes. The company cited a randomized, double-blind, sham-controlled trial published in Molecular Psychiatry. According to the company, that trial showed objective gamma‑frequency normalization measured with MEG and EEG tied to clinical outcomes.

Which neurological and psychiatric indications did Nexalin (NXL) highlight on Feb 2, 2026?

Nexalin highlighted insomnia, depression, PTSD, TBI, Alzheimer’s disease, ADHD, and addiction-related disorders. According to the company, peer-reviewed imaging studies across these indications show network-level modulation associated with symptom improvement.

How does Nexalin (NXL) claim DIFS™ differs from other neurostimulation devices?

The company claims DIFS™ penetrates and regulates deep brain networks rather than delivering superficial, localized stimulation. According to the company, objective imaging across modalities supports deep, whole-brain engagement linked to clinical benefit.

What is the regulatory status reported by Nexalin (NXL) on February 2, 2026 regarding FDA engagement?

Nexalin said it is advancing a “mood-military-memory” clinical business plan with the FDA. According to the company, extensive clinical data have been published and submitted in support of ongoing pre-submission meetings with FDA.